Skip to content
Study details
Enrolling now

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

Antonios Likourezos
NCT IDNCT06473597ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

80

Study length

about 2.3 years

Ages

18–65

Locations

1 site in NY

About this study

Researchers are testing whether Rimegepant (Nurtec) is more effective than Rizatriptan (Maxalt) for treating migraines in adults who go to the Emergency Department. The trial will last 851 days and involve approximately 80 patients.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Rimegepant
  • 2.Take Rizatriptan Benzoate
PhasePhase 4
DrugRimegepant
Routeoral
Primary goalChange in Pain Score at 60 minutes

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

rimegepant, Antimigraine Agents (Serotonin 1b Receptor Agonists)

Drug routes

oral (Disintegrating Oral Tablet), oral (Oral Tablet)

Endpoints

Primary: Change in Pain Score at 60 minutes

Secondary: Change in Pain Score, Functional Status, Headache Medication Efficacy and Tolerability Perception by the Patient

Body systems

Neurology